Canopy Growth (CGC) Return on Capital Employed (2020 - 2025)
Canopy Growth (CGC) reported Return on Capital Employed of 13.14% for Q4 2025, up 637.0% on a YoY basis from 1.78% in Q4 2024, and down 6.84% sequentially from 12.3% in Q3 2025.
Canopy Growth (CGC) Return on Capital Employed (2020 - 2025) Analysis & Trends
Canopy Growth (CGC) has 6 years of Return on Capital Employed data on file, last reported at 13.14% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 637.0% year-over-year to 13.14%; the trailing twelve-month figure through Dec 2025 stood at 13.14% (up 637.0% YoY), and the FY2026 full-year result was 17.11%, down 593.0% from the prior year.
- Return on Capital Employed retreated to 13.14% in Q4 2025, from 12.3% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 12.3% in Q3 2025 to a low of 147.1% in Q1 2023.
- A 5-year average of 40.38% and a median of 19.51% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 12928 bps in 2023 and jumped 12401 bps in 2024, its largest moves.
- Tracing CGC's Return on Capital Employed over 5 years: stood at 12.82% in 2021, then slumped by 745 bps to 108.37% in 2022, then jumped by 52 bps to 51.81% in 2023, then soared by 62 bps to 19.51% in 2024, then soared by 33 bps to 13.14% in 2025.
- Business Quant data shows CGC's Return on Capital Employed at 13.14% in Q4 2025, 12.3% in Q3 2025, and 15.6% in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13.14% |
| Sep 30, 2025 | -12.30% |
| Jun 30, 2025 | -15.60% |
| Dec 31, 2024 | -19.51% |
| Sep 30, 2024 | -26.15% |
| Jun 30, 2024 | -19.17% |
| Mar 31, 2024 | -23.10% |
| Dec 31, 2023 | -51.81% |
| Sep 30, 2023 | -41.69% |
| Jun 30, 2023 | -46.39% |
| Mar 31, 2023 | -147.10% |
| Dec 31, 2022 | -108.37% |
| Sep 30, 2022 | -92.24% |
| Jun 30, 2022 | -64.32% |
| Mar 31, 2022 | -17.82% |
| Dec 31, 2021 | -12.82% |
| Sep 30, 2021 | -17.92% |
| Jun 30, 2021 | -18.32% |
| Mar 31, 2021 | -19.35% |
| Dec 31, 2020 | -30.87% |